CADL Strangle Strategy

CADL (Candel Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

CADL (Candel Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $782.5M, a beta of -0.50 versus the broader market, a 52-week range of 4.35-11.36, average daily share volume of 1.8M, a public-listing history dating back to 2021, approximately 55 full-time employees. These structural characteristics shape how CADL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.50 indicates CADL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on CADL?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

CADL snapshot

As of August 14, 2026, spot at $11.80, ATM IV 125.10%, IV rank 21.77%, expected move 35.87%. The strangle on CADL below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this strangle structure on CADL specifically: CADL IV at 125.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a CADL strangle, with a market-implied 1-standard-deviation move of approximately 35.87% (roughly $4.23 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CADL expiries trade a higher absolute premium for lower per-day decay. Position sizing on CADL should anchor to the underlying notional of $11.80 per share and to the trader's directional view on CADL stock.

CADL strangle setup

The CADL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CADL at $11.80 on that close, the first option leg uses a $12.39 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CADL chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CADL shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$12.39	N/A
Buy 1	Put	$11.21	N/A

CADL strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

CADL strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on CADL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on CADL

Strangles on CADL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CADL chain.

CADL thesis for this strangle

The market-implied 1-standard-deviation range for CADL extends from approximately $7.57 on the downside to $16.03 on the upside. A CADL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CADL IV rank near 21.77% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CADL at 125.10%. As a Healthcare name, CADL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CADL-specific events.

CADL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CADL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CADL alongside the broader basket even when CADL-specific fundamentals are unchanged. Always rebuild the position from current CADL chain quotes before placing a trade.

Frequently asked questions

What is a strangle on CADL?: A strangle on CADL is the strangle strategy applied to CADL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CADL stock at $11.80 on the most recent close, the strikes shown on this page are snapped to the nearest listed CADL chain strike and the premiums come straight from that session's bid/ask midpoint.
How are CADL strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CADL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 125.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CADL strangle?: The breakeven for the CADL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CADL market-implied 1-standard-deviation expected move in the same options snapshot is approximately 35.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on CADL?: Strangles on CADL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CADL chain.
How does current CADL implied volatility affect this strangle?: CADL ATM IV is at 125.10% with IV rank near 21.77%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.